Many European countries ill-prepared to prevent and control the spread of viral hepatitis
Comprehensive national strategies are urgently needed to manage the growing burden of disease
2015-04-23
(Press-News.org) April 23, 2015, Vienna, Austria: Many countries in the World Health Organization (WHO) European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at The International Liver Congress™ 2015.
The study highlights that less than one-third (27%) of WHO European Member States have national strategies in place that contain a surveillance component. Furthermore, only 64% have a national surveillance system for chronic hepatitis B and 61% for chronic hepatitis C.
The study also reveals the main areas in which governments would like the WHO's support:
Development of national plans for viral hepatitis prevention and control (39%)
Estimation of the national burden of viral hepatitis (34%)
Surveillance (23%)
The results were obtained by analysing the responses to surveillance-related questions in the WHO Global Hepatitis Policy Survey. In total, 44 out of 53 (83%) of the WHO European Member States responded to the survey.
The study demonstrates a clear need for better disease surveillance and improvements in the development of national strategies to help prevent and control the spread of viral hepatitis in the WHO European region.
INFORMATION:
About The International Liver Congress™
This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Specialists share research studies and findings, and discuss the hottest topics related to liver disease. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. 2015 is a very special year for EASL and the hepatology community as they will celebrate the 50th annual meeting. The International Liver Congress™ takes place from April 22-26, 2015, Vienna, Austria.
About EASL
Since EASL's foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from more than 100 countries around the world. EASL is the leading liver association in Europe, it attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
Contact
For more information, please contact the ILC Press Office at:
ilc.press@easloffice.eu or
+44 (0)20 3580 5444
ELSE PRESS RELEASES FROM THIS DATE:
2015-04-23
April 23, 2015, Vienna, Austria: A new study revealed today at The International Liver CongressTM 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response at 4 weeks (SVR4) was observed in 98% of patients and in 95% at 12 weeks (SVR12).
The results are particularly encouraging as this patient group is considered difficult-to-treat and has a high mortality rate. The study included 142 patients of different hepatitis C virus (HCV) genotypes who were initiated onto ...
2015-04-23
April 23, 2015, Vienna, Austria: Interim data presented today at The International Liver CongressTM 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients with decompensated cirrhosis. Sustained virologic response (SVR) at 4 weeks was shown to be: sofosbuvir/ribavirin: 75%; sofosbuvir/simeprevir: 77%; sofosbuvir/simeprevir/ribavirin: 81%.
These results demonstrate that all-oral, direct-acting antiviral regimens are better tolerated and achieve higher rates of SVR in HCV ...
2015-04-23
April 23, 2015, Vienna, Austria: Data revealed today at The International Liver Congress™ 2015 highlights the impact of delaying treatment for the hepatitis C virus (HCV). Researchers found that treatment delays have a serious detrimental effect on treatment efficacy, increasing the risk of morbidity and mortality among patients.
The study was conducted using retrospective patient data from the Veterans Administration in the USA to estimate the impact on risk of morbidity and death depending on whether treatment was initiated before or after a patient's FIB4 levels ...
2015-04-23
April 23, 2015, Vienna, Austria: Results revealed today at The International Liver Congress™ 2015 demonstrate current treatment and prevention programmes need to be scaled up in order to make elimination of hepatitis B virus (HBV) possible.
The study conducted by Imperial College Scientists, highlights that if existing interventions, such as infant hepatitis B vaccination and treatment programmes, were scaled up, the number of new chronic HBV infections could be reduced by 90% and mortality levels could be reduced by 65% by 2030. Globally, this would mean 13 million ...
2015-04-23
April 23, 2015, Vienna, Austria: A new device has demonstrated it has the potential to enhance the viability of donor livers for transplantation. Results revealed today at The International Liver Congress™ 2015 show that the transportable machine perfusion (MP) Airdrive® is able to effectively maintain the quality of livers derived from donation after circulatory death (DCD).
Many centers are reluctant to use DCD livers since they might jeopardize graft function post-transplantation. Contrary to 'classical' heart-beating donors (HBD), livers from DCDs undergo ...
2015-04-23
April 23, 2015, Vienna, Austria: New data presented today at The International Liver CongressTM 2015 show that the intensity of weight loss induced by lifestyle changes is strongly linked with the grade of improvement of various histological features of NASH. Weight loss of more than 7% results in a positive impact on most histological parameters; however, to induce steatohepatitis resolution, and fibrosis and portal inflammation improvements, over 10% weight loss is needed.
The study was conducted in 293 patients with histologically proven NASH. Patients were treated ...
2015-04-23
April 23, 2015, Vienna, Austria: A novel immunotherapeutic in early development for chronic hepatitis B (CHB), TG1050, has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB, according to results revealed today at The International Liver Congress™ 2015.
The hallmarks of a CHB cure are:
Elimination of HBsAg - the surface antigen of the hepatitis B virus, and
HBsAg seroconversion - which occurs when a specific antibody becomes detectable in the blood and the corresponding antigen becomes undetectable, in this case ...
2015-04-23
April 23, 2015, Vienna, Austria: Results from a new study demonstrate that chronic hepatitis C virus (HCV) infection is associated with a higher risk of developing cardiovascular diseases and significantly increases cost of care and length of time in hospital. Based on these results, revealed today at The International Liver CongressTM 2015, study investigators conclude that chronic HCV infection should be considered a risk factor for the development of cardiovascular diseases.
In the study, inpatient prevalence of diagnosed HCV infection was 1.9%. For these patients, ...
2015-04-23
April 23, 2015, Vienna, Austria: Data revealed today at The International Liver Congress™ 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95% of patients surviving at 5 years and a significant proportion of deaths coming from liver-unrelated causes.
Long-term ETV or TDF therapy is the most common treatment option in CHB of any severity, but efficacy data have been mainly based upon on-therapy virological remission rates. In this 9-centre, ...
2015-04-23
23 April 2015, Austria, Vienna: Results revealed today at the International Liver Congress™ 2015 show that the daily consumption of capsaicin, the active compound of chilli peppers, was found to have beneficial effects on liver damage.
In the study, capsaicin was found to reduce the activation of hepatic stellate cells (HSCs) in mice models. HSCs are the major cell type involved in liver fibrosis, which is the formation of scar tissue in response to liver damage.
The mice were split into two groups and received capsaicin in their food:
After three days of bile ...
LAST 30 PRESS RELEASES:
[Press-News.org] Many European countries ill-prepared to prevent and control the spread of viral hepatitis
Comprehensive national strategies are urgently needed to manage the growing burden of disease
